Press release from Companies

Publicerat: 2023-03-31 10:49:26

Aptahem AB: BioStock article: Aptahem’s CEO sees continued interest in Apta-1

Aptahem is progressing with its first clinical study with sepsis candidate Apta-1. The company has also ramped up activities to showcase the candidate at domestic and international industry conferences, such as BIO-Europe Spring in Switzerland and TIDES Asia in Japan. BioStock talked to CEO Mikael Lindstam to learn more.

Read the full interview with Aptahem´s CEO Mikael Lindstam at biostock.se:


For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99

About Aptahem

Aptahem AB (APTA) is a clinical stage biotechnology company that develops aptamer-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company’s lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.

Läs mer hos Cision
Läs mer om Aptahem AB

Utskick från Spotlight Group